Shares of Polestar Automotive Holding are surging today after the company said it is expanding its global presence and enhancing its retail strategy to include both existing and new markets as its electric vehicle (EV) lineup grows.
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies